Ticagrelor superior to clopidogrel after ACS

In this trial of >18K patients with ACS, they were randomized to ticagrelor (an oral reversible direct inhibitor of adenosine diphosphate) or clopidogrel. At 1 year, rates of MI/CVA/Vascular death were lower in the ticagrelor group (10%) than the clopidogrel group (12%) with no difference in overall bleeding (abstract). Ticagrelor is superior to clopidogrel in reducing events post-ACS, and is pending FDA approval.

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment